This Bulletin Covers Aspects of Lymphomas and Should Be of Interest to Multidisciplinary s1

Lymphomas November 2014

This bulletin covers aspects of lymphomas and should be of interest to multidisciplinary teams working in this area.

Sections can include:  Combined Modality Therapies  Drug & Biological Therapies  Pathology, Staging, Polymorphisms & Biomarkers  Prognosis, Survival & Risk Factors  Radiotherapy & Imaging  Stem Cell Transplantation  Supportive Care & Symptom Management

Many of the following articles are available online via the NHS Scotland Knowledge Network. Please use the links where provided and your ATHENS password. A complete list of available online journals and registration for ATHENS can be found at www.knowledge.scot.nhs.uk/

If the article you require is not available via the NHS Scotland Knowledge Network and you would like to request a print copy, please submit your request online at www.quest.scot.nhs.uk

This bulletin contains a selection of material gathered from a search of the evidence base, and is not intended to be comprehensive. Professional judgment should be exercised when appraising the material. The Library takes no responsibility for the wording, content and accuracy of the information supplied, which has been extracted in good faith from reputable sources. NHSGGC is not responsible for the content of external internet sites.

Compiled by: Kirsty Coltart Subject Librarian Beatson West of Scotland Cancer Centre 0141 301 7285, [email protected]

General

Calvaruso, M., Gulino, A., Buffa, S., et al. (2014). Challenges and new prospects in hepatosplenic T- cell lymphoma. Leukemia & lymphoma 55,11:2457-2465.

Cheah, C.Y., Campbell, B.A. and Seymour, J.F. (2014). Primary breast lymphoma. Cancer treatment reviews 40,8:900-908.

Coiffier, B., Federico, M., Caballero, D., et al. (2014). Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. Cancer treatment reviews 40,9:1080-1088.

Colosia, A., Njue, A., Trask, P.C., et al. (2014). Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review. Clinical lymphoma, myeloma & leukemia 14,5:343-355.e6.

Goel, A., Fan, W., Patel, A.A., et al. (2014). Nodular lymphocyte predominant hodgkin lymphoma: biology, diagnosis and treatment. Clinical lymphoma, myeloma & leukemia 14,4:261-270.

Jacobson, C. and LaCasce, A. (2014). How I treat Burkitt lymphoma in adults. Blood 124,19:2913- 2920.

Loberiza, F.R.,Jr, Cannon, A.C., Cannon, A.J., et al. (2014). Insights on practice variations in the management of lymphoma and leukemia. Leukemia & lymphoma 55,11:2449-2456.

Montanari, F. and Diefenbach, C. (2014). Relapsed Hodgkin lymphoma: management strategies. Current Hematologic Malignancy Reports 9,3:284-293

Oki, Y., Noorani, M., Lin, P., et al. (2014). Double hit lymphoma: the MD Anderson Cancer Center clinical experience. British journal of haematology 166,6:891-901.

Phillips, E.H., Fox, C.P. and Cwynarski, K. (2014). Primary CNS lymphoma. Current Hematologic Malignancy Reports 9,3:243-253.

Wang, C.C., Carnevale, J. and Rubenstein, J.L. (2014). Progress in central nervous system lymphomas. British journal of haematology 166,3:311-325.

Wilcox, R.A. (2014). Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management. American Journal of Hematology 89,8:837-851.

Combined Modality Therapies

Corradini, P., Vitolo, U., Rambaldi, A., et al. (2014). Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia 28,9:1885-1891.

Crump, M., Kuruvilla, J., Couban, S., et al. (2014). Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. Journal of Clinical Oncology 32,31:3490-3496.

Gerrie, A.S., Power, M.M., Shepherd, J.D., et al. (2014). Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma+. Annals of Oncology 25,11:2218-2223.

Hoppe, B.S., Flampouri, S., Zaiden, R., et al. (2014). Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study. International journal of radiation oncology, biology, physics 89,5:1053-1059.

Kim, S.J., Yang, D.H., Kim, J.S., et al. (2014). Concurrent chemoradiotherapy followed by L- asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Annals of Hematology 93,11:1895-1901.

Rancea, M., von Tresckow, B., Monsef, I., et al. (2014). High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis. Critical Reviews in Oncology-Hematology 92,1:1-10.

Yahalom, J. (2014). Chemotherapy only in early-stage Hodgkin lymphoma: more relapses but "same" (or possibly worse) survival--reconsidering the misguided trend to omit radiotherapy. Current Hematologic Malignancy Reports 9,3:212-216.

Drug & Biological Therapies

Ahearne, M.J., Allchin, R.L., Fox, C.P., et al. (2014). Follicular helper T-cells: expanding roles in T-cell lymphoma and targets for treatment. British journal of haematology 166,3:326-335.

Andrade-Campos, M.M., Montes-Limon, A.E., Soro-Alcubierre, G., et al. (2014). Long-term efficacy of (90)Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life. Annals of Hematology 93,12:1985-1992.

Barr, P.M., Miller, T.P., Friedberg, J.W., et al. (2014). Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Blood 124,8:1259-1265.

Bittenbring, J.T., Neumann, F., Altmann, B., et al. (2014). Vitamin d deficiency impairs rituximab- mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. Journal of Clinical Oncology 32,29:3242-3248.

Chen, Y., Wang, M. and Romaguera, J. (2014). Current regimens and novel agents for mantle cell lymphoma. British journal of haematology 167,1:3-18.

Cheson, B.D. (2014). Which Hodgkin's patients in the Unites States should be treated with BEACOPP?. Current Hematologic Malignancy Reports 9,3:222-226.

Connors, J.M. (2014). Chemotherapy only in early stage Hodgkin lymphoma: more relapses but the same survival--what to do?. Current Hematologic Malignancy Reports 9,3:217-221.

Craig, M., Hanna, W.T., Cabanillas, F., et al. (2014). Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma. British journal of haematology 166,6:920-928.

Evens, A.M., Smith, M.R., Lossos, I.S., et al. (2014). Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. British journal of haematology 166,4:514-520.

Fabbri A. Cencini E. Alterini R. Rubegni P. Rigacci L. Delfino C. Puccini B. Fimiani M. Bosi A. Bocchia M. Pimpinelli N. Gruppo Italiano Linfomi Cutanei (GILC). (2014). Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas. European journal of haematology 93,2:129-136.

Friedberg, J.W., Unger, J.M., Burack, W.R., et al. (2014). R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. British journal of haematology 166,3:382-389.

Garcia-Noblejas, A., Martinez Chamorro, C., Navarro Matilla, B., et al. (2014). Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience. Annals of Hematology 93,9:1551-1558.

Herrera, A.F. and Jacobsen, E.D. (2014). Ibrutinib for the treatment of mantle cell lymphoma. Clinical Cancer Research 20,21:5365-5371.

Jahangiri, S., Friedberg, J. and Barr, P. (2014). Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma. Expert Opinion on Emerging Drugs 19,3:367-383.

Kahl, B.S., Hong, F., Williams, M.E., et al. (2014). Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. Journal of Clinical Oncology 32,28:3096-3102.

Kaplan, J.B., Guitart, J. and Giles, F.J. (2014). Targeted therapies for cutaneous T-cell lymphomas. Expert Review of Hematology 7,4:481-493.

Lim, S.H. and Levy, R. (2014). Translational medicine in action: anti-CD20 therapy in lymphoma. Journal of Immunology 193,4:1519-1524.

Mounier N. Brice P. Bologna S. Briere J. Gaillard I. Heczko M. Gabarre J. Casasnovas O. Jaubert J. Colin P. Delmer A. Devidas A. Bachy E. Nicolas-Virelizier E. Aoudjhane A. Humbrecht C. Andre M. Carde P. Lymphoma Study Association (LYSA). (2014). ABVD (8 cycles) versus BEACOPP (4 escalated cycles > 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Annals of Oncology 25,8:1622-1628.

Murawski, N., Pfreundschuh, M., Zeynalova, S., et al. (2014). Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Annals of Oncology 25,9:1800-1806.

Pardal, E., Coronado, M., Martin, A., et al. (2014). Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. British journal of haematology 167,3:327-336.

Westin, J.R., McLaughlin, P., Romaguera, J., et al. (2014). Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. British journal of haematology 167,2:177-184.

Pathology, Staging, Polymorphisms & Biomarkers

Carbone, A., Gloghini, A., Kwong, Y.L., et al. (2014). Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Annals of Hematology 93,8:1263- 1277.

Eyre, T.A., Collins, G.P., Goldstone, A.H., et al. (2014). Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies. British journal of haematology 166,3:336-351.

Jackson, A.E., Smeltzer, J.P., Habermann, T.M., et al. (2014). The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement. American Journal of Hematology 89,9:865-867.

Marinaccio, C., Nico, B., Maiorano, E., et al. (2014). Insights in Hodgkin Lymphoma angiogenesis. Leukemia research 38,8:857-861.

Ma, J., Lu, P., Guo, A., et al. (2014). Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. British journal of haematology 166,6:849-861.

Ohgami, R.S., Zhao, S. and Natkunam, Y. (2014). Large B-cell lymphomas poor in B cells and rich in PD-1+ T cells can mimic T-cell lymphomas. American Journal of Clinical Pathology 142,2:150-156.

Scott, D.W. and Gascoyne, R.D. (2014). The tumour microenvironment in B cell lymphomas. Nature Reviews.Cancer 14,8:517-534.

Song, G., Gu, L., Li, J., et al. (2014). Serum microRNA expression profiling predict response to R- CHOP treatment in diffuse large B cell lymphoma patients. Annals of Hematology 93,10:1735-1743.

Sui, L., Liu, K., Shen, W., et al. (2014). Relationships between VEGF protein expression and pathological characteristics of diffuse large B cell lymphoma: a meta-analysis. Tumour Biology 35,9:9085-9093.

Warrick, J.I., Owens, S.R. and Tomlins, S.A. (2014). Diffuse large B-cell lymphoma of the prostate. Archives of Pathology & Laboratory Medicine 138,10:1286-1289.

Yoo, C., Yoon, D.H. and Suh, C. (2014). Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor. Blood Research 49,3:148-153.

Yuan, S., Nademanee, A., Kaniewski, M., et al. (2014). Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization. Transfusion 54,8:2015-2021.

Prognosis, Survival & Risk Factors

Ellin, F., Landstrom, J., Jerkeman, M., et al. (2014). Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 124,10:1570-1577.

Shah, B.K., Bista, A. and Shafii, B. (2014). Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States. Anticancer Research 34,9:5117-5120.

Radiotherapy & Imaging

Girinsky, T., Auperin, A., Ribrag, V., et al. (2014). Role of FDG-PET in the implementation of involved- node radiation therapy for Hodgkin lymphoma patients. International journal of radiation oncology, biology, physics 89,5:1047-1052.

Hoink, A.J., Wesling, J., Koch, R., et al. (2014). Comparison of manual and semi-automatic measuring techniques in MSCT scans of patients with lymphoma: a multicentre study. European radiology 24,11:2709-2718.

Kedmi, M., Avivi, I., Ribakovsky, E., et al. (2014). Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography in mantle cell lymphoma?. Leukemia & lymphoma 55,11:2484-2489.

Metser, U., Hussey, D. and Murphy, G. (2014). Impact of (18)F-FDG PET/CT on the staging and management of follicular lymphoma. British Journal of Radiology 87,1042:20140360.

Rutenberg, M.S., Flampouri, S. and Hoppe, B.S. (2014). Proton therapy for Hodgkin lymphoma. Current Hematologic Malignancy Reports 9,3:203-211.

Stewart, D.A., Kloiber, R., Owen, C., et al. (2014). Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma. Leukemia & lymphoma 55,9:2064-2070.

Yamaguchi, S., Hirata, K., Kobayashi, H., et al. (2014). The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma. Annals of Nuclear Medicine 28,7:603-609.

Special Populations

Alexander, S., Kraveka, J.M., Weitzman, S., et al. (2014). Advanced stage anaplastic large cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: A report from the children's oncology group. Pediatric Blood & Cancer 61,12:2236-2242.

Aries, J. and Montoto, S. (2014). Managing HIV and Hodgkin lymphoma in the twenty-first century. Current Hematologic Malignancy Reports 9,3:227-232.

Avivi, I., Farbstein, D., Brenner, B., et al. (2014). Non-Hodgkin lymphomas in pregnancy: tackling therapeutic quandaries. Blood reviews 28,5:213-220.

Friedman, D.L., Chen, L., Wolden, S., et al. (2014). Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate-Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group Study AHOD0031. Journal of Clinical Oncology 32,32:3651-3658.

Goldman, S., Smith, L., Galardy, P., et al. (2014). Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. British journal of haematology 167,3:394-401.

Jachimowicz, R.D. and Engert, A. (2014). The challenging aspects of managing adolescents and young adults with Hodgkin's lymphoma. Acta Haematologica 132,3-4:274-278.

Roth, P. and Hoang-Xuan, K. (2014). Challenges in the treatment of elderly patients with primary central nervous system lymphoma. Current opinion in neurology 27,6:697-701. van Vuren, A. and Meyer-Wentrup, F. (2014). New targets for antibody therapy of pediatric B cell lymphomas. Pediatric Blood & Cancer 61,12:2158-2163.

Wolach, O. and Ram, R. (2014). Adolescents and young adults with non-Hodgkin's lymphoma: slipping between the cracks. Acta Haematologica 132,3-4:279-291.

Supportive Care & Symptom Management

Daniels, L.A., Krol, S.D., de Graaf, M.A., et al. (2014). Impact of cardiovascular counseling and screening in Hodgkin lymphoma survivors. International journal of radiation oncology, biology, physics 90,1:164-171.

Foster, R.H. and Stern, M. (2014). Peer and romantic relationships among adolescent and young adult survivors of childhood hematological cancer: a review of challenges and positive outcomes. Acta Haematologica 132,3-4:375-382.

Jona, A., Miltenyi, Z., Ujj, Z., et al. (2014). Late pulmonary complications of treating Hodgkin lymphoma: bleomycin-induced toxicity. Expert Opinion on Drug Safety 13,10:1291-1297. van Nimwegen, F.A., Schaapveld, M., Janus, C.P., et al. (2014). Risk of diabetes mellitus in long-term survivors of hodgkin lymphoma. Journal of Clinical Oncology 32,29:3257-3263.

Transplantation

Iams, W. and Reddy, N.M. (2014). Consolidative autologous hematopoietic stem-cell transplantation in first remission for non-Hodgkin lymphoma: current indications and future perspective. Therapeutic Advances in Hematology 5,5:153-167.

Khouri, I.F., Wei, W., Korbling, M., et al. (2014). BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood 124,14:2306-2312.

Kruger, W.H., Hirt, C., Basara, N., et al. (2014). Allogeneic stem cell transplantation for mantle cell lymphoma--final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO). Annals of Hematology 93,9:1587-1597.

Porrata, L.F., Inwards, D.J., Ansell, S.M., et al. (2014). Infused autograft lymphocyte to monocyte ratio and survival in diffuse large B cell lymphoma. Biology of Blood & Marrow Transplantation 20,11:1804-1812.

Please note that the journal articles you are accessing are subject to the terms and conditions imposed by the publisher, so there will be a limit on the number of articles an individual may download or print from a single issue of a journal. You can consult your local NHSGGC library with any queries.

If you have any questions regarding this or any other library services please contact Library staff – contact details are at the beginning of the bulletin. Sources used for this bulletin:

OVID databases